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Abstract 
Background: Gastric cancers present late in life with advanced disease and carry a poor prognosis. Polo-like Kinase 
1 (PLK1) is a mitotic kinase with regulatory functions during G2/M and mitosis in the cell cycle. In mammalian cells, 
there is an intricate co-regulatory relationship between PLK1 and the forkhead transcription factor FOXM1. It has been 
demonstrated that individually either PLK1 or FOXM1 expression predicts poorer survival. However, the co-expression 
of both of these markers in gastric adenocarcinomas has not been reported previously.
Methods: We aimed to assess the expression of PLK1 and FOXM1 in Gastric adenocarcinomas in a Western Popula-
tion, to examine whether there is a relationship of PLK1 to FOXM1 in cancer samples. We assess both the protein and 
mRNA expression in this patient population by Tissue Microarray immunohistochemistry and RT-PCR.
Results: Immunohistochemistry was performed on biopsy samples from 79 patients with gastric cancer. Paired 
normal controls were available in 47 patients. FOXM1 expression was significantly associated with gastric adenocarci-
noma (p = 0.001). PLK1 and FOXM1 co-expression was demonstrated in 6/8 (75 %) tumours when analysed by RT-PCR. 
FOXM1 is overexpressed in a large proportion of gastric carcinomas at the protein level and FOXM1 and PLK1 are 
concomitantly overexpressed at the mRNA level in this cancer type.
Conclusions: This study has demonstrated that FOXM1 and its target gene PLK1 are coordinately overexpressed in 
a proportion of gastric adenocarcinomas. This suggests that chemotherapeutic treatments that target this pathway 
may be of clinical utility.
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Background
Gastric adenocarcinoma remains the second common-
est cause of cancer death on a worldwide basis. In the 
West, the incidence has been steadily declining over the 
past few decades [1, 2]. However, in the United King-
dom gastric cancer remains the sixth commonest cause 
of cancer death [3]. This is mainly due to late presenta-
tion of the disease and thus limits treatment options. The 
5-year survival rate is good if the disease is diagnosed at 
an early stage and large scale population screening by 
upper gastrointestinal endoscopy has increased the rates 
of early detection and subsequent prognosis in Japanese 
populations [4, 5]. However, the incidence of gastric 
adenocarcinoma is much lower in the West and large 
scale population screening is not cost effective. Conse-
quently, gastric adenocarcinomas are usually diagnosed 
at an advanced stage and typical 5-year survival is less 
than 15 %. Traditional cytotoxic chemotherapy regimens 
are largely ineffective in halting the disease [6–8]. Even 
when surgery is indicated, neoadjuvant chemotherapy 
improves 5-year survival rates modestly from 20 to 36 % 
[9]. Hence novel treatments and targets for drug thera-
pies are urgently needed to improve outcomes further.
FOXM1 is a member of the forkhead transcription 
factor family, which plays an important role in control-
ling the cell cycle [10, 11]. Specifically, FOXM1 controls 
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mitotic entry through the periodic upregulation of a 
group of genes that are maximally expressed as cells pro-
gress through late G2 and into M phase [12]. Two of its 
target genes are CCNB1 and PLK1, and these form part 
of a kinase-driven positive feedback loop that leads to the 
phosphorylation of FOXM1 and potentiation of its activ-
ity [13, 14]. Hence, there is an intricate inter-regulatory 
relationship between FOXM1 and PLK1 that creates a 
cellcycle control switch. This important link between 
FOXM1 and cellcycle control suggests that it is likely to 
contribute to the aberrant cell proliferation associated 
with malignancy. In clinical settings, FOXM1 has been 
shown to be upregulated in a range of different tumour 
types [11]. More recently, FOXM1 was shown to be over-
expressed and of potential prognostic significance in 
oesophageal adenocarcinomas and squamous carcino-
mas [15, 16]. In the same fashion, the FOXM1 target gene 
PLK1 has also been shown to be overexpressed in a wide 
range of tumours [17], including oesophageal adeno- and 
squamous carcinomas [15, 18, 19]. Furthermore, novel 
molecular functions for FOXM1 have been identified 
in cancer cells beyond simply the acceleration of G2–M 
phase progression [11, 20]. This is exemplified by its abil-
ity to promote the nuclear translocation of β-catenin in 
gliomas, and consequently it can activate a whole pro-
gramme of Wnt target genes [21]. Taken together, these 
findings indicate that FOXM1 and PLK1 are likely central 
regulators in carcinogenesis and are therefore potential 
therapeutic targets.
In the current study, we investigate the expression of 
FOXM1 and PLK1 in gastric adenocarcinomas with par-
ticular emphasis on examining whether there is evidence 
that FOXM1and PLK1 are co-ordinately expressed. We 
aimed to show that there is a relationship of PLK1 to 
FOXM1 in cancer samples. Such co-regulation in cancer 
samples has not previously been investigated; as studies 
have been limited to studying either FOXM1 or PLK1 
expression in these tumours [22, 23]. We previously dem-
onstrated co-upregulation of these proteins in oesopha-
geal adenocarcinomas [15]. We now show that there is 
also coordinate overexpression of FOXM1 and PLK1 in 
gastric adenocarcinomas, thereby providing the poten-
tial for feedback potentiation of FOXM1 activity. PLK1 
inhibitors are currently being developed for cancer ther-
apy [17, 24] and it is likely that cells demonstrating coor-
dinated up regulation of FOXM1 and PLK1 expression 
will be particularly susceptible to such treatment.
Methods
Tissue collection
The Wrightington, Wigan and Leigh NHS Local Research 
and Ethics Committee initially granted ethical approval 
in 2007. Tissue was obtained a total of 79 gastric 
carcinomas and 47 healthy controls have been directly 
recruited. Patients who had received neo-adjuvant chem-
otherapy were excluded. Paraffin Blocks were also used to 
construct slides for immunohistochemistry.
Demographic Information, including age at diagno-
sis, sex, co-morbidity and survival was collected on all 
patients. Tumour grade and stage were documented 
using the TNM and AJCC criteria. Biopsy samples were 
collected during endoscopy from the tumour and where 
possible from macroscopically normal adjacent tissue at 
least 5  cm away from macroscopic evidence of tumour. 
Endoscopic biopsy samples were then either snap-fro-
zen in liquid nitrogen or collected in RNAlater (Qiagen 
Laboratories)©. They were then archived at −80 °C until 
needed. A small number of surgical samples were also 
taken. These were dissected from the tumour and adja-
cent normal tissue by a histopathologist immediately 
after removal from the patient. Surgical samples were 
frozen in liquid nitrogen and then stored at −80 °C. Sam-
ples were used for RNA extraction and protein analysis.
Immunohistochemistry
Tissue microarray (TMA) blocks were constructed 
from surgical tumour block resections and biopsies 
as described previously in our laboratory [15]. Three 
arrays were constructed for each case and stained with 
mouse anti-PLK1 antibody (Zymed 37-7100) or Rabbit 
polyclonal anti-FOXM1 antibody (SC-500, Santa Cruz, 
FoxM1 K19 antibody) as previously described [15]. The 
slides were scored jointly by JC, MD and SH using a 
Nikon Eclipse 50 Microscope (blinded). The slides were 
also scanned using a MIRAX 3Dhistotech system for ref-
erence and archive purposes. The scores were calculated 
by subjectively assessing nuclear intensity on a score of 
zero to three. The percentage of cells showing nuclear 
staining was documented to the nearest five percent. An 
overall score was obtained by multiplying the intensity by 
the percentage.
RNA isolation and RT–PCR analysis
RNA was extracted, it’s integrity determined and sub-
sequent real-time RT–PCR performed for PLK1 and 
FOXM1 RNA using SYBR Green as described previously 
[15]. RNA samples from all human tissue specimens were 
validated using an Agilent 2100 bioanalyser with a RNA 
6000 Nano assay lab chip kit. For relative comparison of 
mRNA levels from tissue specimens, data were further 
normalised to the level of each gene in a stock standard 
concentration of RNA isolated from Het1a cells. The cell 
lines were cultured and lysed as described previously 
[15].
RT-PCR primers were designed using the internet pro-
grams Primer 3 (http://frodo-wi.mit.edu/primer3/input.
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htm) and NCBI primer blast (http://www.ncbi.nlm.nih.
gov/tools/primer-blast/). All primers were designed to 
cross an intron-extron junction sequence to minimize 
amplifying genomic DNA contamination. Ribosomal 
18S RNA, β-actin, and GAPDH were assessed as house-
keeping genes for the normalization of the clinical biopsy 
samples and samples were ultimately normalized to 18S 
RNA.
Statistics
SPSS 16.0 (IBM®, New York, USA) was used for statis-
tical analysis. The paired T test was used to compare 
continuous variables. Chi-Square, Mann–Whitney U 
(nominal variables with two values) and Kruskal–Wal-
lis (nominal variables with multiple values) were used to 
compare discrete variables. Kaplan–Meier analysis was 
used to calculate survival curves by univariate and multi-
variate analysis respectively. Significance was accepted to 
be present with a p value of less than 0.05.
Results
FOXM1 protein expression
Samples were obtained from 79 patients with gastric 
adenocarcinomas in a large general hospital with an 
established cancer surgical service (Table 1). 47 patients 
had paired normal gastric tissue obtained >5  cm from 
the edge of the tumour. Tissue microarrays (TMAs) 
consisting of biopsies of clinical endoscopic and surgi-
cal resection specimens were constructed. The expres-
sion of FOXM1 was then probed using the FOXM1 K19 
antibody.
First, to confirm the validity of the FOXM1 antibody 
and assess protein expression in tumour samples we per-
formed western blot analysis of FOXM1 expression in 
corresponding tissue types from 3 types of gastrectomy 
specimens: normal tissue (N), high grade dysplasia (D) 
and tumour (T). This is suggestive of enhanced levels of 
FOXM1 protein in both dysplastic tissue and gastric ade-
nocarcinomas (Fig.  1, lanes 3 and 6). Next we analysed 
FOXM1 protein expression using the TMAs. FOXM1 
was shown to cause predominant nuclear staining in 
gastric adenocarcinomas, although some cytoplasmic 
staining was seen (Fig.  2a). Staining of varying degrees 
was seen across the cores. For the negative controls sec-
tions we have pre-incubated the antibody with its pep-
tide and there was no staining, hence we are confident 
of its specificity. As it is a commercially available anti-
body, we use a standardised positive control and hence 
confident of the sensitivity. Gastric adenocarcinoma 
samples had a higher IHC score than paired normal tis-
sues (Fig. 2b) (Paired T test p =  0.001) IHC. Moderate 
to high FOXM1 expression was significantly associated 
with gastric adenocarcinoma compared to non-cancer 
tissue (Mann–Whitney U p =  0.001) (Fig.  2c). FOXM1 
positive expression was seen in up to 55 % of the paired 
normal gastric tissues but of these 65 % were low posi-
tive expression. There were no significant differences 
between FOXM1 expression and tumour depth, nodal 
metastasis, distant metastasis or AJCC stage (Fig.  2d). 
FOXM1 expression did not have a correlation between 
survival or recurrence in gastric adenocarcinomas (data 
not shown).
Table 1 Demographics, clinical staging, treatments 
and FOXM1 protein expression in gastric tissue
The number of cases is illustrated, percentages are in brackets. The number 
of patients with missing data is indicated. Positive expression was taken as an 
immunohistochemistry score of > 90 and High positive expression was taken 
as an immunohistochemistry score > 150. P values calculated by Chi2  test are 
indicated
Normal gastric tissue Gastric adenocarci-
noma
Number of cases 47 79
Male 30 (64 %) 46 (58 %) (p = 0.87)
Age 69 ± 9 70 ± 11 (p = 0.94)
Pathological differentiation
 Poor 40 (51)
 Moderate 28 (35)
 Well 9 (11)
 Missing 2 (3)
Depth of invasion
 T1 8 (10)
 T2 22 (28)
 T3 42 (53)
 T4 5 (6)
Missing 1 (1)
Metastatic disease
 Local (N) 53 (67)
 Distant (M) 4 (5)
AJCC 2010 stage
 1 15 (19)
 2 22 (28)
 3 31 (39)
 4 9 (11)
 Missing 1 (1)
Treatment
 Surgery 65 (82)
 Surgery and chemo-
therapy
5 (6)
 Chemotherapy 6 (8)
 Palliative care 2 (3)
 Missing 1 (1)
FOXM1 mRNA expression
 Positive expression 26 (55) 56 (71) (p = 0.001)
 High positive expres-
sion
1 (2) 23 (29) (p = 0.001)
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PLK1 and FOXM1 mRNA expression in Gastric 
Adenocarcinoma
Having established up-regulation of FOXM1 protein 
expression in gastric cancers, we next wanted to test 
whether we could detect co-upregulation of PLK1. How-
ever we were unable to find a suitable antibody for IHC 
so instead we turned to RT-PCR analysis. We quantified 
FOXM1 and PLK1 mRNA expression using real-time 
RT-PCR and normalised mRNA levels to 18S ribosomal 
RNA. Samples from 22 patients were included in the 
study with patients being divided into tissue groups. The 
groups included tissue from macroscopically normal gas-
tric epithelium from healthy controls (n = 13) and gastric 
adenocarcinoma patients (n = 8). The clinical details are 
indicated in Table 2.
The expression levels of both PLK1 and FOXM1 mRNA 
are higher in gastric adenocarcinoma tissue compared to 
gastric tissue from healthy controls (Fig.  3a, b). Median 
expression levels are increased ninefold for both PLK1 
(paired T test p  =  0.007) and FOXM1 (paired T test 
p  =  0.001) (Fig.  3c). 5/8 (63  %) tumour samples dem-
onstrated high levels of PLK1 and FOXM1. Importantly 
there was a strong correlation between FOXM1 levels 
with PLK1 expression levels across all the samples tested 
(R2  =  0.608; Fig.  3d) suggesting a direct co-regulatory 
relationship. No normal samples expressed high levels of 
PLK1 and FOXM1. Given the small sample size it is not 
appropriate to analyse mRNA expression levels for clini-
cal correlations.
Discussion
In this study we have demonstrated that FOXM1 pro-
tein, and PLK1 and FOXM1 mRNA levels are all mark-
ers of gastric adenocarcinoma when compared to normal 
gastric tissue. Importantly, we provide evidence for co-
upregulation of FOXM1 and PLK1 expression in these 
cancers as predicted from their co-regulatory associa-
tion. Previous groups have demonstrated FOXM1 over-
expression in cancer [15, 25, 26]. FOXM1 has previously 
been shown to be overexpressed in 88 % of gastric ade-
nocarcinomas in a cohort of Chinese patients [26]. PLK1 
has separately been reported to be overexpressed in gas-
tric cancer patients [22, 27]. Our results are consistent 
with this and confirm the overexpression of both FOXM1 
protein and mRNA in gastric cancer. We did not find any 
associations with clinical characteristics or prognosis 
within our immunohistochemistry analysis. Li et al. [25] 
demonstrated a highly significant association between 
immunohistochemical expression of FOXM1 and prog-
nosis. Both studies had similar number of therapeutic 
characteristics. The reason for the differences in prognos-
tic association is unclear. It is possible that there was a 
difference in the numbers of proximal and distal gastric 
cancers between the two groups or other factors between 
our British population that differ from the American 
population in their study. It can be surmised there was a 
general consistency between both our protein and RNA 
results and these overexpression seen by other groups in 
gastric cancer.
It is perhaps of interest to assess whether PLK1 or 
FOXM1 have utility aiding with prognostic assessment 
and identifying populations that might respond to tar-
geted therapies. The data from our Real time RT-PCR 
analysis of PLK1 and FOXM1 in cancer samples did not 
show a statistically significant survival benefit in either 
the surgical or non-surgical patient group. This may be 
as a result of the heterogenicity of the small gastric can-
cer population in the samples we collected. Clinically 
homogenous populations are more useful for assessing 
survival benefit. American and UK groups have previ-
ously used microarray data from surgical patients with 
oesophageal cancer to demonstrate two and four gene 
signatures that have prognostic value [23, 28]. PLK1 
was found to be a potential prognostic marker by one 
of these studies although this was not further validated 
[23]. Validation of microarray findings is important 
because there can be poor correlations between qRT-
PCR and normalized microarray data for up to 16 % of 
genes [29].
PLK1 inhibitors are in active development as oncology 
treatments [30]. It is possible that PLK1 inhibition will be 
of clinical utility in treating gastric cancer patients. Ini-
tial phase II trials including those utilising BI 2536 have 
been disappointing with no patients with advanced dis-
ease having a complete or partial response [31]. Drug 
limiting effects including neutropenia, thrombocytope-
nia and anaemia were observed frequently. It is therefore 
unsurprising that the major limiting side effects relate to 
impairment of rapidly proliferating tissues given PLK1’s 
Fig. 1 FOXM1 protein expression in gastric tissue. Western blots of 
FOXM1 protein expression in the indicated tissue type are shown. 
Molecular weights are in kDa. Results of normal gastric mucosa (N) 
and Tumour (T) or high grade dysplasia (D) in specimens 571,565,187 
from three gastrectomies are shown. Flo1 cell lysate is shown in the 
left lane. ERK2 was used as a loading control
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major role in regulating the cell cycle. Whilst patients did 
not gain a significant clinical response to BI2536 treat-
ment it is worth noting that some tumour types did enter 
a period of stable non-progressive disease, particularly 
ovarian cancer patients [31]. A recent phase I clinical trial 
which used another PLK1 inhibitor GSK461364, found 
that stable disease was achieved for greater that 4 months 
in 6/40 patients [32]. Interestingly all of the responders to 
treatment had significantly higher PLK1 and KI67 levels 
when assessed by immunohistochemistry. This may sug-
gest PLK1 inhibition may be of most use in the subset of 
patients with overexpression of FOXM1 and it’s target 
genes.
Conclusion
It is clear that both PLK1 and FOXM1 are tightly regu-
lated to prevent inappropriate proliferation, and both 
have widespread interactions throughout the cell cycle. 
Carcinogenesis is a dynamic process with changes in 
the genome, transcriptome, intra/extracellular signalling 
throughout the tumour, as well as alterations to the sur-
rounding vascular and stromal tissue. Whilst our results 
Fig. 2 FOXM1 protein expression in gastric tissue assessed by immunohistochemistry. a Tissue microarrays stained by FOXM1 antibody showing 
normal epithelium, negative, low, moderate and high staining of gastric adenocarcinoma at ×20 and ×40. b The proportion of patients in each 
category with negative-low FOXM1 staining (white bar) and moderate-high FOXM1 staining (black bar) is shown. c Boxplot of FOXM1 protein 
expression in gastric tissue. Median values of FOXM1 expression are indicated for each tissue type (indicated by horizontal bar). **P value <0.01. d 
The histogram demonstrates FOXM1 expression (grouped as negative, low, moderate or high) in relation to AJCC stage as assessed by immunohis-
tochemistry
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Table 2 Demographics, clinical staging, treatments, PLK1 mRNA and FOXM1 mRNA expression of the patients in each tis-
sue group
The number of cases is shown in each category, percentages are in brackets. mRNA levels are mean expression levels and standard deviation relative to 18S ribosomal 
RNA and standards derived from HET1a cell lines. The number of patients with clinical data missing is indicated. Positive expression is defined as an expression level 
equal or higher to the mean of the normal sample plus two standard deviations about the mean for the indicated gene. P values calculated by Chi2  test are indicated
HGD high grade dysplasia, EMR endoscopic mucosal resection
Gastric normal Gastric adenocarcinoma
Number of cases 13 8 (1HGD)
Male 4 (31) 7 (88) (p = 0.02)
Age 72 ± 3 70 ± 4 (p = 0.45)
Smoking
 Never 1 (8) 1 (11) (p = 0.45)
 Ex-smoker 1 (8) 2 (22) (p = 0.98)
 Current 5 (38) 6 (67) (p = 0.09)
 Missing 6 (46) 0
Pathological differentiation
 Poor 6 (75)
 Moderate 0
 Well 0
 Missing 2 (25)
Depth of invasion
 T1 1 (13)
 T2 2 (25)




 Local (N) 3 (37.5)
 Distant (M) 0 (0)
AJCC 2010 Stage
 1 2 (25)
 2 3 (36)
 3 2 (25)
 4 0
 Missing 1 (13)
Treatment
 Surgery 6 (75)




 Palliative care 1 (13)
 Missing 0
PLK1 mRNA expression
 mRNA level ×10 2.1 18.8
 Positive expression 2 (15) 5 (63) (p = 0.056)
FOXM1 mRNA expression
 mRNA level ×10 1.2 9.2
 Positive expression 0 (0) 6 (75) (p = 0.001)
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Fig. 3 PLK1 and FOXM1 expression in normal gastric tissue and gastric adenocarincoma. a Histograms of the mRNA levels of PLK1 and FOXM1 
relative to 18S mRNA in gastric tissue. Data was standardized relative to the gene expression in stock mRNA samples prepared from the Het1a cell 
line. The average relative mRNA level and standard deviations derived from two readings from one sample are shown. The individual tissue speci-
mens are numbers and samples are grouped by tissue sub-types. The mean gene expression in each category is shown in red. Positive expression 
(calculated as two standard deviations above the mean of the value in normal samples) is illustrated by the horizontal dotted line. b Box plots of PLK1 
and FOXM1 mRNA expression. The box plot demonstrates the interquartile range. Median expression values are indicated by the horizontal lines. c 
Scatterplot indicating the expression of FOXM1 relative to PLK1 mRNA expression. R2 value is indicated
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suggest that both PLK1 and FOXM1 are implicated in 
carcinogenesis in gastric adenocarcinoma, blockade of 
one regulatory pathway is unlikely to halt cancer progres-
sion and induce widespread apoptosis in  vivo. Increas-
ingly more recent cancer therapies often involve blockade 
of multiple pathways using a combination of therapeutic 
agents and it may be that targeting FOXM1 pathways will 
prove a useful treatment adjunct.
Work is already being undertaken in our laboratory to 
identify new FOXM1 target genes using ChIP-seq tech-
nologies. Future work will focus on using gene expression 
array data to assess alternative FOXM1 targets and novel 
FOXM1 interactions in gastric cancer. FOXM1’s multiple 
potential roles in carcinogenesis suggest that the devel-
opment of chemotherapy that targets the FOXM1 regula-
tory network may have clinical utility.
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